Summit Therapeutics Inc
NASDAQ:SMMT

Watchlist Manager
Summit Therapeutics Inc Logo
Summit Therapeutics Inc
NASDAQ:SMMT
Watchlist
Price: 17.82 USD 4.58% Market Closed
Market Cap: 13.3B USD

P/E
Price to Earnings

-59.9
Current
-11.4
Median
24.1
Industry
Lower than median
Lower than industry value

The Price to Earnings (P/E) ratio shows how much investors are willing to pay for each dollar of a company’s earnings. It’s calculated by dividing the company’s market value by its net income.

P/E
-59.9
=
Market Cap
13.3B USD
/
Net Income
-221.3m USD
All Countries
Close
Earnings Growth PEG
US
Summit Therapeutics Inc
NASDAQ:SMMT
Average P/E: 191
Negative Multiple: -59.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 995.2 N/A N/A
US
Abbvie Inc
NYSE:ABBV
170.7
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
25.1
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
19
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
31.5
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -530.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
9%
2
AU
CSL Ltd
ASX:CSL
18.7
11%
1.7
NL
argenx SE
XBRU:ARGX
34.4
40%
0.9
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 210.8
N/A N/A

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
-14.4
2-Years Forward
P/E
-18
3-Years Forward
P/E
-18.6